Porges to Bio­gen: I don’t like your neu­ro­path­ic pain drug; Ex-Mod­er­na ex­ec Bolen joins PureTech as CSO

Leerink’s Ge­of­frey Porges is pour­ing cold wa­ter over Bio­gen’s rax­a­t­rig­ine (BI­IB074), a neu­ro­path­ic pain drug it ob­tained in their $675 mil­lion deal to buy Con­ver­gence. Writes Porges: “We be­lieve that Bio­gen’s neu­ro­path­ic pain treat­ment can­di­date rax­a­t­rig­ine (BI­IB074) faces long-odds due to the poor record of the class and trou­bling de­vel­op­ment his­to­ry of this mol­e­cule; ear­ly sig­nals are en­cour­ag­ing but at this stage we don’t see enough con­sis­tent ev­i­dence of ben­e­fit to add this to our mod­el and val­ue propo­si­tion for Bio­gen.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER